The inhibitor of apoptosis (IAP) protein survivin is highly expressed in cancers, but not in normal differentiated tissues. TCF/b-catenin signaling has been reported to participate in the regulation of survivin transcription in colon cancer. We have recently characterized ICG-001, a small molecule specific inhibitor of the b-catenin/ Creb-binding protein (CBP) interaction. Inhibition of the b-catenin/CBP interaction represses a subset of TCF/bcatenin-mediated transcription. ICG-001 potently inhibits survivin gene transcription and expression. ICG-001-mediated downregulation of survivin expression enhanced caspase-3 activity and apoptosis, which was rescued by overexpression of wild type but not mutant (C84A) survivin. Small interfering RNA and genetic reduction of CBP also decreased survivin expression. Chromatin immunoprecipitation assay confirmed that CBP is the crucial coactivator for TCF/b-catenin-mediated survivin transcription. Furthermore, ICG-001-induced recruitment of p300 to the survivin promoter led to concomitant recruitment of SUMO-1, HDAC6 and PML proteins, which have been associated with transcriptional repression. These findings demonstrate that CBP and p300 play very distinct roles in survivin gene transcription.
Introduction
Survivin is a member of the inhibitor of apoptosis (IAP) family of proteins that is prominently upregulated in many human cancers (Ambrosini et al., 1997; Tamm et al., 1998; Altieri, 2003a, b; Li, 2003) , yet virtually undetectable in normal adult tissues. It is the fourth most abundant 'transcriptome' that is selectively expressed in cancerous but not normal tissue (Velculescu et al., 1999) . Survivin like other IAP family members inhibits apoptosis induced by a variety of agents (e.g. TNFa, chemotherapeutics, oxidative stress and viral infection) potentially via direct or indirect interaction with effector caspases-3/7 and 9 (LaCasse et al., 1998; Deveraux and Reed 1999; O'Connor et al., 2000) . Survivin is associated with the mitotic apparatus where it plays an essential role in maintaining high fidelity at cell-cycle checkpoints and transitions Speliotes et al., 2000) . Homologous disruption of the survivin locus leads to very early embryonic lethality with exhibition of gross nuclear abnormalities and failed cytokinesis . Interference with survivin expression by antisense RNA, or by expression of a dominant-negative mutant, results in caspase activation and cell-cycle-dependent apoptosis O'Connor et al., 2000) . The mechanisms controlling survivin gene transcription in cancer cells remain elusive. Recent studies in colon cancer cells suggest that regulation of survivin expression is at least partially TCF/b-catenin dependent (Zhang et al., 2001; Kim et al., 2003) . Other transcription factors, that is, Sp1 have also been reported to play important roles in survivin transcription Xu et al., 2004) . TCF/b-catenin-mediated signaling regulates a diverse set of genes responsible for cell proliferation, differentiation and homeostasis (Giles et al., 1998) . We have recently synthesized and characterized a small molecule (ICG-001) that specifically blocks a subset of TCF/bcatenin transcriptional events by binding to the coactivator Creb-binding protein (CBP) but not its highly homologous relative p300, thereby disrupting the bcatenin/CBP interaction (Emami et al., 2004) . We now wish to report, utilizing both chemogenomic inhibition with ICG-001 and small interfering RNA (siRNA), that survivin transcription via TCF/b-catenin signaling is critically dependent on the coactivator CBP. Furthermore, utilizing chromatin immunoprecipitation assay (ChIP), we demonstrate that coactivator switching from CBP to p300 at the survivin promoter is associated with the recruitment of transcriptionally repressive elements.
Results

ICG-001 inhibits survivin gene transcription and expression in cancer cells
Previously we determined that ICG-001 selectively binds to CBP, but not the highly homologous coactivator p300, thereby blocking the CBP/b-catenin interaction leading to attenuation of TCF/b-catenin signaling as judged by TOPFLASH and assessment of the transcriptional activity of a subset of downstream target genes (Emami et al., 2004) . In a cDNA microarray analysis using the Clontech Atlas Human Cancer 1.2 Array (#7851-1) in the human colon cancer cell line SW480 (Emami et al., 2004) , we observed a marked reduction in the transcription of survivin (B70%), along with markers of cell proliferation: PCNA (B67%), Ki67 (B55%) and cyclinD1 (B50%), a well-characterized TCF/b-catenin-dependent target gene. To further investigate the regulation of survivin transcription, we demonstrated that ICG-001 dose dependently inhibited luciferase activity (IC 50 ¼ 5.870.7) driven by the survivin full-length promoter luciferase construct pGL3b-6270 (Figure 1a ), as well as inhibiting survivin gene transcription and expression in two colon carcinoma cell lines, SW480 and HCT116 (Emami et al., 2004) . A dramatic reduction in survivin levels in SW480 cells was also observed by immunocytochemistry (Figure 1b) . These cell lines display high constitutive TCF/b-catenin transcription as assessed by the TOPFLASH reporter assay due to abnormally high b-catenin nuclear accumulation caused by either APC mutation (SW480) (Goyette et al., 1992) or b-catenin mutation (HCT116) (Ilyas et al., 1997) . Abrogation of survivin mRNA ( Figure 1c ) and expression ( Figure 1d ) by ICG-001 was also demonstrated in ER þ and ERÀ breast, and AR þ and ARÀ prostate cancer cells. These cell lines show significant b-catenin accumulation in the nucleus, where it interacts with TCF4 and CBP/p300 as judged by immunoblotting and coimmunoprecipitation (data not shown). These results are in agreement with other findings suggesting that nuclear b-catenin accumulation plays an important role in Wnt activation and transcription of downstream target genes, that is, survivin, cyclin D1, in both breast (Lin et al., 2000; Bafico et al., 2004) and prostate cancer development (Chesire and Isaacs, 2003) . This suggests that survivin gene transcription in a variety of cancer cell lines is TCF/b-catenin regulated in a CBP-dependent fashion.
Survivin expression is regulated in a TCF/b-catenin/CBPdependent manner
To further address the significance of these observations, we examined the transcription of survivin using the minimal survivin reporter construct pGL3b-420 (Kim et al., 2003) , which contains two consensus TCF-binding elements (TBEs), in three isogenic HCT116 cell lines, that is, parental HCT116 cells (wt/*) carrying one wildtype allele (wt) and one oncogenic b-catenin allele (*), Hb18 (ko/*) that have the wild-type allele genetically deleted (ko), and Hb92 (wt/ko) in which the oncogenic allele is genetically deleted. TOPFLASH activity among the isogenic lines was initially evaluated. As anticipated from the work of Waldman and co-workers (Kim et al., 2002) , parental HCT116 cells displayed the highest activity; Hb18 showed no significant difference, whereas Hb92 cells, in which the oncogenic b-catenin allele is deleted, had a 68% reduction in activity compared to the parental HCT116 cells (data not shown). The parental HCT116 cells displayed the highest survivin reporter activity among the three cell lines. Hb18 and Hb92 demonstrated a modest (13-16%) reduction compared to the parental line, with no statistically significant difference between them (Figure 2a ). The modest reduction in survivin promoter reporter activity in the Hb18 cells could be due to an additive effect between the oncogenic and wild-type forms of b-catenin protein on survivin expression in the parental cells. Similar effects have been observed on BMP-4 expression in these cell lines (Kim et al., 2002) . The absence of further reduction in survivin reporter activity in the Hb92 cells suggests that the deleted oncogenic b-catenin allele is not essential for survivin expression. Consistent with the reporter gene assays, immunoblotting also revealed no difference in the level of survivin protein between Hb18 and Hb92, but both were lower than the parental HCT116 cells (Figure 2b ). Nuclear translocation of b-catenin is critical to the activation of the canonical Wnt signaling pathway, which regulates survivin transcription as well as many other TCF/bcatenin target genes, including cyclin D1, c-myc and BMP-4 (He et al., 1998; Tetsu and McCormick, 1999; Zhang et al., 2001; Kim et al., 2003) . However, our results suggest that survivin expression is only partially dependent on the nuclear translocation of b-catenin. To further clarify this, we transfected parental HCT116 (Figure 2c ). These results confirm that the TBEs indeed participate in survivin transcription. Our data demonstrate that in Hb92 cells, the oncogenic b-catenin allele is not required to maintain substantial levels of survivin transcription. This suggests that TCF may recruit an alternative binding partner (e.g. g-catenin) to promote survivin transcription. g-Catenin is a closely related homolog of b-catenin, which has been previously reported to have TCFdependent transcriptional activity in b-catenin-deficient cells (Maeda et al., 2004) . We detected upregulation of g-catenin in the nucleus of Hb92 cells, whereas no g-catenin was detected in the nucleus in the parental HCT116 and Hb18 cells ( Figure 2d ). The role of g-catenin in regulating survivin expression was confirmed in NCI-H28 cells, a cell line in which the gene for b-catenin is homozygously deleted, but has strong g-catenin expression (Maeda et al., 2004) . NCI-H28 cells display strong survivin expression. g-Catenin interacts strongly with CBP, and this association is specifically disrupted by ICG-001, leading to a reduction in survivin transcription as judged by RT-PCR (data not shown). We conclude that the increased accumulation of g-catenin in the nucleus of Hb92 cells partially compensates for the loss of activated b-catenin in TCF/catenin-mediated survivin expression.
ICG-001 interferes with the interaction of CBP and catenin; therefore we anticipated that removal of the TBEs in the survivin promoter would right-shift the dose-response curve for ICG-001. To test this hypothesis, we transfected the pGL3b-420 survivin reporter construct and the corresponding null-TBE construct, pGL3b-DTCF420, into HCT116 cells in the presence of ICG-001. Survivin promoter reporter activity was attenuated in a dose-dependent fashion in both cases, however as anticipated, the pGL3b-DTCF420 transfectants showed significantly higher IC 50 (5.971.6 mM) and IC 90 values (IC 90 >30 mM) than the pGL3b-420 transfectants (IC 50 : 2.971.2 mM; IC 90 : B20 mM) (Figure 2e ). Collectively, these results clearly demonstrate that TCF/ catenin signaling participates, albeit not exclusively, in regulating survivin gene transcription in a TCF/catenin/ CBP-dependent fashion.
CBP association at the survivin promoter is critical in tumor cells
Based upon the selectivity of ICG-001 (Emami et al., 2004) , we anticipated that CBP, but not p300, is crucial for survivin transcription. To confirm this, we examined the endogenous occupancy at the survivin promoter for TCF4 and b-catenin using the ChIP assay in SW480 cells in the presence or absence of ICG-001. As shown in Figure 3 , both TCF4 and b-catenin are clearly associated with the survivin promoter (panel a, lanes 3-5 and 8-10) in both treated and nontreated cells. The degree of TCF4 and b-catenin occupancy is not notably altered by ICG-001 treatment (panel a, compare lanes 4 and 5 vs 3, 9 and 10 vs 8). This was anticipated given the mechanism of action of the compound. We next investigated the recruitment of CBP and p300 to the survivin promoter. CBP, but not p300, was prominently associated with the survivin promoter in the absence of ICG-001 (panel b, lanes 1 and 3). ICG-001 significantly reduced CBP occupancy at the survivin promoter, yet unexpectedly increased p300 occupancy (panel b, lanes 2 and 4). We have observed similar results in HCT116 (panel C, lanes 7 and 8 and 9 and 10) as well as in two breast carcinomas cell lines, MCF7 and MDA-MB-231 (data not shown).
CBP but not p300 is critical for survivin gene transcription and expression
To substantiate the essential role of CBP in survivin transcriptional regulation, we cotransfected mouse embryonic fibroblasts (MEFs) with a constitutively translocating form of b-catenin (pCMV-ptb-catenin) and either full-length CBP (pCMV-CBP) or p300 (pCMV-p300). MEF cells exhibit minimal TOPFLASH or survivin promoter reporter activity without activation of the canonical Wnt pathway (Figure 4a 2) . Importantly, overexpression of p300 failed to compensate for CBP in survivin transcriptional regulation (Figure 4c, lanes 7-9) . The enhanced survivin reporter activity seen in the CBP and b-catenin cotransfectants was further supported by immunoblotting, which demonstrated that the level of survivin protein is notably upregulated in CBP cotransfectants (Figure 4d , compare lanes 4 and 3), but remains unchanged in p300 cotransfectants (Figure 4d , compare lanes 5 and 3). We conclude that CBP but not p300 is critical for survivin expression.
Next, we utilized siRNA to specifically deplete either endogenous CBP or p300 to examine the effects on survivin expression. We transiently transfected SW480 cells with double-stranded siRNA, human CBP (siR-NA CBP ) and p300 (siRNA p300 ), and immunoblotted for p300 and CBP from nuclear extracts and survivin from the cytosolic fraction. As seen in Figure 5a , both p300 (panel a, lane 5) and CBP (panel b, lane 6) levels were significantly and selectively reduced by their respective siRNAs and not by the nonspecific siRNA controls (panels a and b, lanes 3 and 4). ICG-001 does not affect the overall level of CBP or p300 expression (panels a and b, lanes 1 and 2). As expected, only siRNA CBP transfectants displayed a significant reduction in survivin protein (panel d, lane 6) albeit not as dramatic as the reduction seen upon treatment with ICG-001 (panel d, lanes 1 and 2). Neither siRNA p300 transfectants nor the controls had any affect on the level of survivin. This demonstrates that specific reduction of CBP but not p300 is associated with decreased survivin expression. Finally, we investigated the level of survivin expression in genetically modified MEF cell lines, that is, wild-type (wt), heterozygous deficient CBP ( þ /À) and heterozygous deficient p300 ( þ /À). Immunoblotting confirmed lower CBP and p300 levels in the CBP ( þ /À) and the p300 ( þ /À) cells, respectively, than in the wildtype cells (Figure 5b) . We then examined endogenous survivin mRNA and expression in these three cell lines. As anticipated, of the three cell types, CBP ( þ /À) cells displayed the lowest, while p300 ( þ /À) cells the highest level of survivin message and expression (Figure 5c ). Taken together, we conclude that CBP is essential for survivin gene expression.
Recruitment of p300 to the survivin promoter leads to the recruitment of repressive transcriptional elements and transcriptional repression ICG-001 prevents the association of CBP with the survivin promoter (Figure 3 , panels b and c), yet despite the fact that survivin mRNA levels were significantly Differential roles for CBP and p300 on survivin expression H Ma et al decreased, curiously increased p300 association was observed at the survivin promoter (Figure 3 , panels b and c). Several recent reports have also demonstrated a role for p300 in transcriptional repression (Suganuma et al., 2002; Baluchamy et al., 2003; Girdwood et al., 2003) . Therefore, we investigated if ICG-001-induced p300 recruitment to the survivin promoter is associated with the recruitment of additional repressive transcriptional elements, that is, SUMO-1 and HDAC6 (Girdwood et al., 2003) . ChIP assay demonstrated that ICG-001 induced recruitment of p300, presumably via TCF/ b-catenin (Figure 3a) , concomitantly increased the occupancy of SUMO-1 (Figure 6a , compare lanes 7 and 8), and HDAC6 (Figure 6a , compare lanes 5 and 6) dramatically, and PML modestly (Figure 6a , compare lanes 9 and 10), to the survivin promoter complex. This suggests that recruitment of repressive elements to the survivin promoter by p300 is associated with survivin transcriptional repression.
To investigate the effect of p300 levels on survivin transcription, we utilized the survivin promoter reporter construct (pGL3b-6270) after depleting either endogenous CBP or p300 with siRNA. As anticipated, depletion of CBP using siRNA CBP led to a B30-40% reduction in survivin promoter luciferase activity (Figure 6b , compare lanes 4 and 6), whereas depletion of p300 with siRNA p300 significantly enhanced survivin promoter luciferase activity (Figure 6b , compare lanes 5 and 6). Utilizing the TOPFLASH reporter construct, both siRNA CBP and siRNA p300 decreased luciferase activity approximately 50% (Figure 6b, lanes 1-3) . Consistently, cotransfection of pGL3b-6270 with CBP upregulated survivin promoter luciferase activity, whereas, cotransfection with p300 caused a significant downregulation in SW480 (Figure 6c ). These data suggest that recruitment of p300 and subsequently repressive transcriptional elements to the survivin promoter is associated with a reduction of survivin transcription. Immunoblotting analysis for CBP and p300 in MEF wild-type, heterozygous deficient CBP ( þ /À) and heterozygous deficient p300 ( þ /À) cells. Histone H3 was used as the nuclear loading control. (C) Survivin mRNA and protein levels were determined by real-time RT-PCR and immunoblotting for MEF wild-type, CBP ( þ /À) and p300 ( þ /À) cells. a-Tubulin was used as the protein loading control Differential roles for CBP and p300 on survivin expression H Ma et al
ICG-001 sensitizes transformed cells to apoptosis through inhibition of survivin expression
ICG-001 selectively induces caspase-3/7 activity in colon carcinoma cells, in which survivin is highly expressed (Emami et al., 2004) . We anticipated that ICG-001 selectively activates caspases significantly via downregulation of survivin expression. To examine this, we performed the following series of experiments. SW480 cells were treated with 0.5 mM staurosporine (STS), a natural product broad spectrum of protein kinase inhibitor originally isolated from the bacterium Streptomyces staurosporeus (Omura et al., 1977) . This led to an approximately twofold increase in caspase-3 activity relative to vehicle control ( Figure 7A , compare lanes 1 and 2). In combination with 5 mM ICG-001, a dose that alone showed no significant induction of caspase-3 activity ( Figure 7A , lane 3), but effectively suppressed survivin promoter luciferase activity (Figure 1a) , STSinduced caspase-3 activity was enhanced approximately fivefold compared to vehicle control ( Figure 7A , compare lanes 4 and 1), and a greater than twofold compared to STS alone ( Figure 7A , compare lanes 4 and 2). The elevated caspase-3 activity concomitantly increased DNA fragmentation, a hallmark of cellular apoptosis, up to 73% as assessed by propidium iodide (PI) staining and flow cytometric analysis ( Figure 7B , boxes a-d). STS also induced caspase-2 activity, but no increased activity was detected when 5 mM ICG-001 was added (data not shown). Neither survivin, nor any other IAPs have been reported to inhibit caspase-2 activation (Kumar and Vaux, 2002) .
Next, we asked whether the enhanced caspase activation and cellular apoptosis induced by ICG-001 was due to the downregulation of survivin expression. To determine this, we transfected cells with either full-length human survivin (pCMV-hSurvivin wt ) or a dominant-negative C84A mutant (pCMV-hSurvivin C84A ) expression construct . ICG-001-enhanced caspase-3 activation and DNA fragmentation was largely abolished by transfection with pCMV-hSurvivin (Jiang et al., 1996) . p53 transcriptional activation is enhanced by binding to CBP (Miyagishi et al., 2000) . However, the synergistic effect of ICG-001 on STS-induced apoptosis in this study is likely independent of p53, as the p53 gene is mutated in SW480 cells (Abarzua et al., 1995) . We, therefore, conclude that ICG-001 sensitizes caspase-3 activation and cellular apoptosis in cancer cells significantly via downregulation of survivin expression.
Discussion
We demonstrate that TCF/b-catenin-dependent survivin gene transcription is regulated in a CBP-dependent fashion. The small molecule inhibitor ICG-001 binds specifically to CBP, thereby disrupting the b-catenin/ CBP interaction. Utilizing a chemogenomic approach, we demonstrate that ICG-001 effectively suppresses survivin promoter-dependent luciferase activity, as well as endogenous survivin message and expression in colorectal, breast and prostate cancer cells. Further depletion of endogenous CBP through the use of siRNA, or utilization of a heterozygous deficient CBP cell line (CBP þ /À) confirms that reduced levels of endogenous CBP are sufficient to suppress survivin message and expression. We have also demonstrated that ICG-001 treatment reduced the occupancy of CBP and increased the recruitment of p300 to the survivin promoter with concomitant increased recruitment of SUMO-1, HDAC6 and PML. SUMO-1 and HDAC6 have been reported to be associated with p300-mediated transcriptional repression (Girdwood et al., 2003) and PML4 was recently implicated in survivin transcriptional repression (Xu et al., 2004) . Finally, we show that ICG-001 sensitizes caspase-3 activation and apoptosis in colorectal cancer cells in conjunction with staurosporine treatment. The sensitizing effect is rescued by transfection of wild-type survivin, but not by its inactive C84A mutant. Survivin is critical for mitotic progression and the maintenance of cell-cycle checkpoint fidelity Uren et al., 2000; O'Connor et al., 2002) . Functional studies indicate that reduction of endogenous survivin through transfection of dominant-negative or antisense survivin triggers spontaneous apoptosis and cell-cycle defects, features of which include multipolar spindles, multinucleation and polyploidy . We, however, did not observe a significant increase in multipolar spindle cells or polyploidy at 25 mM ICG-001, as might be expected if the compound specifically blocked survivin expression. Rather, we observe cell-cycle arrest primarily at G0/G1 in colon cancer cells (data not shown). This is fully consistent with the fact that ICG-001 does not exclusively target survivin expression. ICG-001 binds specifically to CBP, and in so suppresses a subset of TCF/b-cateninmediated transcription, including survivin. In addition, abrogation of TCF/b-catenin/CBP signaling by ICG-001 simultaneously downregulates the expression of cyclin D1, a well-recognized TCF/b-catenin-dependent target gene (Tetsu and McCormick, 1999; Shtutman et al., 1999) , leading to cell-cycle arrest at G0/G1. Intriguingly, the expression of c-myc, another wellrecognized TCF/b-catenin target (He et al., 1998) , is concomitantly increased along with recruitment of p300 to the c-myc promoter (Kahn et al., unpublished results). The differential effects of ICG-001 on the expression of these TCF/b-catenin-regulated genes may enhance the apoptotic induction observed (Evan et al., 1992; Pelengaris et al., 2002) .
It is becoming apparent that despite their high degree of homology and similar patterns of expression, CBP and p300 play unique and distinct roles in gene regulation (Goodman and Smolik, 2000) . Our study presents strong evidence that CBP and p300 have distinct functions in the regulation of survivin transcription. The results are consistent with recent publications suggesting nonredundant roles for CBP and p300 in cell growth, differentiation and development, in spite of their high degree of homology (Kawasaki et al., 1998; Yao et al., 1998; Kung et al., 2000; Yamauchi et al., 2002; Roth et al., 2003) . Rebel et al. (2002) , using a hematopoietic stem cell (HSC) model, concluded that CBP but not p300 is essential for HSC self-renewal, whereas p300 is critical for proper hematopoietic differentiation. Kawasaki et al. (1998) found that p300, but not CBP, is absolutely required for RAinduced F9 differentiation. Furthermore, MEF heterozygous deficient CBP ( þ /À) cells proliferate at a significantly slower rate than their heterozygous p300 ( þ /À) MEF counterparts. Survivin is abundantly expressed in the more rapidly proliferating p300 ( þ /À) cells, but scarcely in the less rapidly dividing CBP ( þ /À) cells, further reinforcing the critical role of CBP in proliferation. Based on the data reported in this manuscript, as well as additional microarray data (data not shown), we propose that TCF/catenin/CBP-driven transcription is critical for proliferation without differentiation (e.g. in cancer and stem cells), whereas a switch to TCF/catenin/p300-mediated gene expression is an essential initial step in normal cellular differentiation. This model is fully consistent with the previous results of Rebel et al. (2002) and Kawasaki et al. (1998) .
ChIP assays reveal that ICG-001 is capable of preventing the association of CBP with the survivin promoter, while somewhat unexpectedly inducing the recruitment of p300. At the concentration utilized in the ChIP assay, ICG-001 dramatically decreases survivin mRNA and expression. Taken together, these results suggest that recruitment of p300 to the survivin promoter is a critical step to initiate transcriptional repression. Consistent with this interpretation, we further demonstrate that overexpression of p300 in SW480 colon carcinoma cells leads to a reduction in survivin promoter reporter luciferase activity (Figure 6c) . Furthermore, Suganuma et al. (2002) reported that reintroduction of p300, but not CBP, into human carcinoma cells acts as a tumor suppressor. A role for Differential roles for CBP and p300 on survivin expression H Ma et al p300 as a corepressor in gene transcription, although not as well documented as its role in coactivation, is not without precedence (Baluchamy et al., 2003; Lee et al., 2004) . Although the exact mechanism(s) by which p300 may act to repress survivin gene transcription is still unclear, a recent report suggests that SUMO-1 modification of p300 results in HDAC6 recruitment, resulting in transcriptional suppression (Girdwood et al., 2003) . A role for PML4 in reducing survivin expression has also been reported recently (Xu et al., 2004) . We have observed that upon treatment with ICG-001, SUMO-1 and HDAC6 are strongly recruited to the survivin promoter region together with p300. A plausible mechanism for the repression of survivin transcription by ICG-001 involves the orchestrated attenuation of CBP/b-catenin binding, subsequent recruitment of p300 to the promoter by b-catenin, modification by SUMO-1, and subsequent sequestration of HDAC6, PML and potentially additional repressive transcriptional components. SiRNA-depletion of endogenous p300 led to enhancement, while overexpression of p300 led to partial repression, of survivin promoter reporter activity. The significance of p300-mediated survivin repression may be dependent upon the status of cell transformation, canonical Wnt signaling activation, endogenous levels of CBP and p300 as well as other factors. Furthermore, genetically reduced expression of CBP in MEF cells leads to downregulation of survivin transcription and expression. Interestingly, we have observed three promoter-specific differential outcomes in colorectal cancer cells at TCF/b-catenin-regulated gene promoters upon disrupting the b-catenin/CBP interaction with ICG-001. At the cyclin D1 promoter, we observed a decrease in message and no recruitment of p300 (Emami et al., 2004) , at the c-myc promoter, we observed an increase in message with increased p300 occupancy (data not shown), whereas at the survivin promoter, we observed increased recruitment of p300 along with additional proteins associated with transcriptional repression and a corresponding decrease in survivin message (Figure 8 ). Further studies to explore promoter-specific coactivator usage and their respective transcriptional outcomes are in progress.
Survivin is a promising target in cancer therapy (Altieri, 2003a, b; Li, 2003) . Expression of the survivin gene has been associated with poor prognosis in various cancers (Adida et al., 2000) . Replication-deficient adenoviral targeting of survivin has been shown to be as effective in tumor reduction as Taxol and more effective than Adriamycin in breast and gastric cancer xenograft models in nude mice (Tu et al., 2003) . The CBP-specific inhibitor ICG-001, through its selective transcriptional effects and particularly, its ability to reduce survivin expression both in vitro and in vivo Differential roles for CBP and p300 on survivin expression H Ma et al (Emami et al., 2004) , represents an attractive lead for the development of new cancer chemotherapeutics. In particular, targeting the CBP/catenin interaction may be particularly relevant to dealing with the vexing problem of cancer stem cells (Owens and Watt, 2003) .
Materials and methods
Plasmids
The survivin promoter luciferase construct (pGL3b-420) containing 585 nucleotides upstream of the initiating ATG of the human survivin gene was subcloned from the pLuc6270 reporter construct (a kind gift from Dr F Li, Roswell Park Cancer Research Institute) into the pGL3-basic vector (Promega, Madison, WI, USA). The À585 bp fragment harbors two TBEs, TBE2 (À465) and TBE3 (À411), proximal to the ATG site (Kim et al., 2003 ) was constructed essentially as described by Tu et al. (2003) .
Cell culture, transient transfection and luciferase reporter assays
Human colon cancer (SW480), prostate cancer (LNCaP and PC-3) and breast cancer cell lines (MCF7, MDA-MB-468 and MDA-MB-231) from ATCC were grown according to the supplier's instructions. Isogenic b-catenin-deleted cell lines Hb18 (ko/*) and Hb92 (wt/ko), and the parental HCT116 (wt/ *) were the kind gift of Dr Todd Waldman (Lombardi Cancer Center, Georgetown School of Medicine). Genetically modified MEF cell lines (wild-type, heterozygous deficient CBP ( þ /À) and p300 ( þ /À) were kindly provided by Dr Vivienne Rebel (Dana-Farber Cancer Institute), and cultured in DMEM supplemented with 10% FBS and 5% sodium bicarbonate solution (Gibco, CA, USA). Transient transfections were carried out in six-well plate using Superfectt (Qiagen, CA, USA) with 1 mg/well plasmid DNA. To examine the inhibition by ICG-001 of survivin promoter luciferase activity, the transfected cells were harvested and reseeded on white-opaque 96-well plates, to which the desired doses of ICG-001 were added. Luciferase activity was measured after 24 h using the dual luciferase assay system (Promega), and relative luciferase units (RLU) were calculated following normalization with Renilla luciferase counts. Percent inhibition survivin reporter activity ¼ (RLU treated: survivin reporter -RLU treated: vector control )/(RLU vehicle control: survivin reporter -RLU vehicle control: vector control ) Â 100%. pGL3-basic was used as the vector control.
Real-time PCR
Total RNA was extracted (RNeasy Midit Kit, Qiagen, CA, USA), and first-strand cDNA synthesis was performed (TaqMan RT, Roche Molecular Miochemical, IN, USA). Realtime RT-PCR was performed with the SYBR Green PCR Master Mix kit (Perkin Elmer Biosystems Shelton, CT, USA) using the following primers: human survivin F 5 0 -agccctttcaag gaccac-3 0 , R 5 0 -gcactttcttcgcagtttcc-3 0 ; human b-actin F 5 0 -cctcgcctttgccgatcc-3 0 , R 5 0 -ggatcttcatgaggtagtcagtc-3 0 ; mouse survivin F 5 0 -gtacctcaagaactaccgcatc-3 0 , R 5 0 -gtcatcgggttcc cagccttcc-3 0 . Data were analysed by the threshold cycle (Ct) comparative method. The 2
ÀDDCt value was calculated, where DCt ¼ Ct survivin -Ct bÀactin , and DDCt ¼ DCt sample -DCt reference .
Immunoblotting
Whole-cell lysates, cytosolic and nuclear fractions were prepared as per the manufacturer's instructions (Piece) and total protein was equally loaded (25 mg/well), separated on 4-20% gradient SDS-PAGE (Invitrogen, CA, USA), and transferred to immobilon-P (PVDF) membranes (Millipore, MA, USA). The membranes were blocked with 5% (w/v) skim milk in TBST buffer (15 mM Tris/HCl, pH 7.4, 0.9% NaCl 0.05% Tween 20) and incubated with primary antibodies, survivin, CBP and p300, purchased from Santa Cruz Biotechnology or otherwise specified. The membranes were developed using ECL (Amersham, Pharmacia Biotech, UK). To ensure no contamination between the cytosolic and nuclear fractions, each sample was carefully examined for the presence or absence of cytosolic markers (b-actin or a-tubulin).
ChIP assay
ChIP assays were conducted essentially as described in Spencer et al. (2003) . Immunoprecipitation was performed with antibodies against TCF4 (Upstate, NY, USA), b-catenin (Upstate, NY, USA), CBP, p300 and acetylated histone H3 (Upstate, NY, USA). The captured immunocomplexes containing bound transcriptional DNA fragments were eluted, and the recovered DNA fragments were used for PCR using primers specifically amplifying the native human survivin promoter, F: 5 0 -ggggcgctaggtgtggg-3 0 and R: 5 0 -ttcaaatctggcgg ttaatggc-3 0 .
CBP and p300 siRNA analysis Double-stranded siRNA with a tt overhang at the 3 0 end (Proligo, CO, USA) specifically targeting human CBP (antisense: 5 0 -gcggcuguugauuccucaa-3 0 ) or p300 (antisense: 5 0 -agaugagaguuuaggccgc-3 0 ) were transfected into SW480 cells (Superfectt,Qiagen). Knockdown of endogenous CBP or p300 and survivin expression was determined by immunoblotting blotting as previously described.
Immunochemistry
Cells were seeded on coverslips in a six-well plate for 12 h prior to treatment. Treated cells were collected, fixed with chilled MeOH and permeablized with 1 Â PBS and Triton 100. The coverslips were incubated with specific antibodies against human survivin (Cell Signaling Technology, MA, USA) and atubulin. The appropriate secondary antibody conjugated with either FITC or TRITC was applied. The coverslips were mounted on slides and examined using a Nikon PCM 2000 Laser Scanning Confocal Microscope.
Caspase-3 activity and cell-cycle analysis
Fluorescence-based caspase-3 activity was assayed with 200 mg total protein per sample according to the manufacturer's protocol (R&D Systems, MN, USA). Relative fluorescence units (RFU) for each sample were obtained by subtracting the unit values of blanks, and fold changes were calculated as the ratio of treated to vehicle control (VC). Cell-cycle analysis; cells were fixed with 70% chilled ethanol for at least 30 min, washed once with 1 Â PBS, and incubated with PI solution (50 mg/ml). A total of 10 000 cells were acquired using a Beckman Coulter EPICS XL-MCL Flow Cytometer, and the percentage of subG 0 /G 1 cell population, as an estimate of DNA fragmentation, was determined using Expo32 ADC software (Coulter Corporation, FL, USA).
